Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Prognosis prediction beyond MTV using easy to calculate parameters derived from FDG-PET/CT, a pilot Study

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSándor CziborBKBernadett KálmánHAHussain Alizadeh

Discussion

Loading...

Member takes

Overview

Pilot study shows prognostic biomarkers enhance risk stratification for DLBCL, indicating new evaluation methods may be needed.

Key Points

  • Dmax/Volume lesion and TLG-inverse improve risk stratification in DLBCL patients, enhancing prognostic accuracy.
  • Receiver operating characteristic analysis revealed significant predictive capacity for the new metrics alongside MTV.
  • Kaplan-Meier analyses confirmed differentiation between high- and low-risk groups based on imaging biomarkers and clinical outcomes.
  • Novel imaging parameters may augment existing prognostic tools, highlighting the need for further validation in larger studies.

Cite This Study

Czibor et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e415https://doi.org/10.1182/blood-2025-3665
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Total metabolic tumor volume as a prognostic biomarker in high-burden follicular lymphoma: A systematic review and meta-analysis2025
  2. 2Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy2025
  3. 3Comparison of different response evaluation criteria in interim PET/CT for diffuse large B-cell lymphoma: is Δtotal metabolic tumor volume a worthwhile measure?2025
  4. 4Prognostic Value of Metabolic Tumor Volume and Heterogeneity Index in Diffuse Large B-Cell Lymphoma.2025
  5. 5Prognostic value of baseline FDG PET/CT total metabolic tumor volume and MYC/BCL2 double expression status in patients with diffuse large B-cell lymphoma2025